OncoMatch/Clinical Trials/NCT06704191
In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial
Is NCT06704191 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including BCG Solution and Docetaxel for non-muscle invasive bladder carcinoma.
Treatment: BCG Solution · Docetaxel · Gemcitabine · Mitomycin — This phase Ib/II trial compares the safety, tolerability and acceptability of intravesical chemotherapy given at home to in-clinic administration in patients with non-muscle invasive bladder cancer. Chemotherapy drugs, such as bacillus Calmette-Guerin (BCG), gemcitabine, docetaxel, and mitomycin C, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Standard of care chemotherapy for non-invasive bladder cancer is usually given directly into the bladder through a catheter (intravesical). This process requires numerous visits and can be disruptive to the lives of patients and caregivers. Bringing cancer care to the patients with in-home intravesical therapy may help reduce the disruption to daily lives. In-home intravesical chemotherapy may be safe and tolerable and may also be preferable to in-clinic administration in patients with non-muscle invasive bladder cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Urothelial Carcinoma
Disease stage
Required: Stage TIS
Prior therapy
Must have received: intravesical therapy (gemcitabine, gemcitabine/docetaxel, bacillus Calmette-Guerin, mitomycin C) — induction (Phase IB) or maintenance (Phase II)
currently receiving induction therapy with one of the following eligible intravesical treatment regimens (gemcitabine, sequential gemcitabine/docetaxel, Bacillus Calmette-Guerin, Mitomycin C) [Phase IB]; receiving maintenance therapy with an eligible regimen [Phase II]
Cannot have received: other investigational or standard of care agent for non-muscle invasive bladder cancer
Exception: eligible treatment regimens
Receiving any other investigational or standard of care agent which would be considered as a treatment for non-muscle invasive bladder cancer and is not part of the eligible treatment regimens
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic in Florida · Jacksonville, Florida
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify